Literature DB >> 30110164

Positron Emission Tomography (PET) Ligand Development for Ionotropic Glutamate Receptors: Challenges and Opportunities for Radiotracer Targeting N-Methyl-d-aspartate (NMDA), α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA), and Kainate Receptors.

Hualong Fu1, Zhen Chen1, Lee Josephson1, Zijing Li2, Steven H Liang1.   

Abstract

Ionotropic glutamate receptors (iGluRs) mediate excitatory neurotransmission within the mammalian central nervous system. iGluRs exist as three main groups: N-methyl-d-aspartate receptors (NMDARs), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), and kainate receptors. The past decades have witnessed a remarkable development of PET tracers targeting different iGluRs including NMDARs and AMPARs, and several of the tracers have advanced to clinical imaging studies. Here, we assess the recent development of iGluR PET probes, focusing on tracer design, brain kinetics, and performance in PET imaging studies. Furthermore, this review will not only present challenges in the tracer development but also provide novel approaches in conjunction with most recent drug discovery efforts on these iGluRs, including subtype-selective NMDAR and transmembrane AMPAR regulatory protein modulators and positive allosteric modulators (PAMs) of AMPARs. These approaches, if successful as PET tracers, may provide fundamental knowledge to understand the roles of iGluR receptors under physiological and pathological conditions.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30110164      PMCID: PMC6393217          DOI: 10.1021/acs.jmedchem.8b00714

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  140 in total

Review 1.  Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography.

Authors:  Marc Laruelle; Mark Slifstein; Yiyun Huang
Journal:  Mol Imaging Biol       Date:  2003 Nov-Dec       Impact factor: 3.488

Review 2.  Structure and gating of the glutamate receptor ion channel.

Authors:  Lonnie P Wollmuth; Alexander I Sobolevsky
Journal:  Trends Neurosci       Date:  2004-06       Impact factor: 13.837

3.  Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro.

Authors:  D J Smith; R L Bouchal; C A deSanctis; P J Monroe; J B Amedro; J M Perrotti; T Crisp
Journal:  Neuropharmacology       Date:  1987-09       Impact factor: 5.250

Review 4.  Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists.

Authors:  Mark E Layton; Michael J Kelly; Kevin J Rodzinak
Journal:  Curr Top Med Chem       Date:  2006       Impact factor: 3.295

5.  Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.

Authors:  Carol Addy; Chris Assaid; David Hreniuk; Mark Stroh; Yang Xu; W Joseph Herring; Aaron Ellenbogen; H A Jinnah; Louis Kirby; Mark T Leibowitz; R Malcolm Stewart; Daniel Tarsy; James Tetrud; S Aubrey Stoch; Keith Gottesdiener; John Wagner
Journal:  J Clin Pharmacol       Date:  2009-06-02       Impact factor: 3.126

6.  In vivo study of NMDA-sensitive glutamate receptor by fluorothienylcyclohexylpiperidine [correction of fluorothienylcycloexylpiperidine], a possible ligand for positron emission tomography.

Authors:  C Ferrarese; A Guidotti; E Costa; R S Miletich; K C Rice; B R de Costa; M J Fulham; G Di Chiro
Journal:  Neuropharmacology       Date:  1991-08       Impact factor: 5.250

Review 7.  The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies.

Authors:  Paul L Chazot
Journal:  Curr Med Chem       Date:  2004-02       Impact factor: 4.530

8.  NMDA-receptor activity visualized with (S)-[N-methyl-11C]ketamine and positron emission tomography in patients with medial temporal lobe epilepsy.

Authors:  E Kumlien; P Hartvig; S Valind; I Oye; J Tedroff; B Långström
Journal:  Epilepsia       Date:  1999-01       Impact factor: 5.864

9.  Radiosynthesis and pharmacological evaluation of [11C]EMD-95885: a high affinity ligand for NR2B-containing NMDA receptors.

Authors:  G Roger; F Dollé; B De Bruin; X Liu; L Besret; Y Bramoullé; C Coulon; M Ottaviani; M Bottlaender; H Valette; M Kassiou
Journal:  Bioorg Med Chem       Date:  2004-06-15       Impact factor: 3.641

Review 10.  The molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors.

Authors:  Claire L Palmer; Lucy Cotton; Jeremy M Henley
Journal:  Pharmacol Rev       Date:  2005-06       Impact factor: 25.468

View more
  9 in total

1.  Synthesis and Preliminary Evaluations of a Triazole-Cored Antagonist as a PET Imaging Probe ([18F]N2B-0518) for GluN2B Subunit in the Brain.

Authors:  Hualong Fu; Weiting Tang; Zhen Chen; Vasily V Belov; Genwei Zhang; Tuo Shao; Xiaofei Zhang; Qingzhen Yu; Jian Rong; Xiaoyun Deng; Wei Han; Scott J Myers; Pilar Giffenig; Lu Wang; Lee Josephson; Yihan Shao; April T Davenport; James B Daunais; Mikhail Papisov; Hongjie Yuan; Zijing Li; Stephen F Traynelis; Steven H Liang
Journal:  ACS Chem Neurosci       Date:  2019-02-27       Impact factor: 4.418

Review 2.  Research Progress on Alzheimer's Disease and Resveratrol.

Authors:  Yan Yan; Huihuang Yang; Yuxun Xie; Yuanlin Ding; Danli Kong; Haibing Yu
Journal:  Neurochem Res       Date:  2020-03-11       Impact factor: 3.996

3.  Evaluation of 11C-NR2B-SMe and Its Enantiomers as PET Radioligands for Imaging the NR2B Subunit Within the NMDA Receptor Complex in Rats.

Authors:  Lisheng Cai; Jeih-San Liow; Cheryl L Morse; Sanjay Telu; Riley Davies; Michael P Frankland; Sami S Zoghbi; Ken Cheng; Matthew D Hall; Robert B Innis; Victor W Pike
Journal:  J Nucl Med       Date:  2020-01-10       Impact factor: 10.057

4.  Dopamine and glutamate in schizophrenia: biology, symptoms and treatment.

Authors:  Robert A McCutcheon; John H Krystal; Oliver D Howes
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

Review 5.  Genetics of glutamate and its receptors in autism spectrum disorder.

Authors:  Sabah Nisar; Ajaz A Bhat; Tariq Masoodi; Sheema Hashem; Sabah Akhtar; Tayyiba Akbar Ali; Sara Amjad; Sanjeev Chawla; Puneet Bagga; Michael P Frenneaux; Ravinder Reddy; Khalid Fakhro; Mohammad Haris
Journal:  Mol Psychiatry       Date:  2022-03-16       Impact factor: 13.437

Review 6.  Glutamatergic Dysfunction and Glutamatergic Compounds for Major Psychiatric Disorders: Evidence From Clinical Neuroimaging Studies.

Authors:  Cheng-Ta Li; Kai-Chun Yang; Wei-Chen Lin
Journal:  Front Psychiatry       Date:  2019-01-24       Impact factor: 4.157

7.  The Mechanism of Downregulated Interstitial Fluid Drainage Following Neuronal Excitation.

Authors:  Yuanyuan Li; Hongbin Han; Kuangyu Shi; Dehua Cui; Jun Yang; Ian Leigh Alberts; Lan Yuan; Guomei Zhao; Rui Wang; Xianjie Cai; Ze Teng
Journal:  Aging Dis       Date:  2020-12-01       Impact factor: 6.745

8.  Translational medicine of the glutamate AMPA receptor.

Authors:  Tomoyuki Miyazaki; Hiroki Abe; Hiroyuki Uchida; Takuya Takahashi
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2021       Impact factor: 3.493

Review 9.  A Review of Molecular Imaging of Glutamate Receptors.

Authors:  Jong-Hoon Kim; János Marton; Simon Mensah Ametamey; Paul Cumming
Journal:  Molecules       Date:  2020-10-16       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.